Research & Development

Research & DevelopmentCurrent Status of Clinical Trials

Type Cell type Product Indication predecessor award Phase I clinical trial Phase II clinical trial Clinical III Award Applied technology

Autologous Immunocytes CBT101* solid cancer (Recurrent Glioblastoma )
Allogenic Immunocytes Allo-NK solid cancer
Neuropathic cells FMD-NPC Parkinson’s Disease (PD)
Stem cell CordSTEM-DD Disk Degeneration
CordSTEM-ST Stroke
CordSTEM-AS Asherman's syndrome
CordSTEM-ARDS Severe respiratory disease
ES-MSC premature ovarian failure
hESC-RPE Macular Degeneration (AMD)
hESC-RPE Stargard's disease

*U.S. FDA designates rare drug for recurrent malignant neuropods (2020.9)
CHA Biotech program Partnered program

CEO Message
Overseas Corporations
Affiliated Companies
Business Overview
Cord Blood Banking Business
Bio Insurance Business
CHAUM Business(Non-medical)
IT Business
Other Business
CHA Biotech R&D Center
R&D Pipeline
Current Status of Clinical Trials
Patent Grants (Korea/Overseas)
Scientific Publications
IR Presentations